| abstract |
The present invention relates generally to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly, to novel substituted heterocyclic azole compounds, the synthesis of these compounds and their pharmaceutical compositions and their usefulness in the treatment, Modulate and/or prevent physiological conditions associated with CRM1 activity, for example in the treatment of cancer and other neoplastic diseases, inflammatory diseases including cardiomyopathy, diffuse interstitial pulmonary fibrosis, liver fibrosis, glomerulonephritis, and others Use in abnormal tissue growth and fibrotic disorders of renal disease, and in viral infections (acute and chronic). |